Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar monotherapy in drug-naïve type 2 diabetes
NCT01871428Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of aleglitazar in type 2 diabetes mellitus (T2DM), sponsored by Roche. Started Jun 2013; status: completed.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01871428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871428.